Despina Siolas
Overview
Explore the profile of Despina Siolas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
954
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Metzger D, Greenspun B, Siolas D, Jafari M
Ann Surg Oncol
. 2025 Feb;
PMID: 40009308
No abstract available.
2.
Metzger D, Greenspun B, Brouwer J, Li Y, Pigazzi A, Siolas D, et al.
Ann Surg Oncol
. 2025 Feb;
PMID: 39948314
Background: Whereas clinicopathologic risk factors for colon cancer (CC) recurrence are well-established, the role of genomic predictors remains understudied. This study aimed to identify genomic factors associated with recurrence after...
3.
McIntyre C, Grimont A, Park J, Meng Y, Sisso W, Seier K, et al.
Cancer Cell
. 2024 Aug;
42(9):1614-1629.e5.
PMID: 39214094
KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) are suggested to vary in oncogenicity but the implications for human patients have not been explored in depth. We examined 1,360 consecutive PDAC...
4.
Narayan V, Siolas D, Meadows E, Turzhitsky V, Sillah A, Imai K, et al.
JCO Clin Cancer Inform
. 2023 Oct;
7:e2300096.
PMID: 37906722
Purpose: Treatment of non-muscle-invasive bladder cancer (NMIBC) is guided by risk stratification using clinical and pathologic criteria. This study aimed to develop a natural language processing (NLP) model for identifying...
5.
Kasi P, Hidalgo M, Jafari M, Yeo H, Lowenfeld L, Khan U, et al.
Oncogene
. 2023 Sep;
42(44):3252-3259.
PMID: 37731056
In patients with locally advanced cancer without distant metastases, the neoadjuvant setting presents a platform to evaluate new drugs. For mismatch repair proficient/microsatellite stable (pMMR/MSS) colon and rectal cancer, immunotherapy...
6.
Wan S, Zhao E, Freeman D, Weissinger D, Krantz B, Werba G, et al.
Front Immunol
. 2023 Apr;
14:1177713.
PMID: 37033968
[This corrects the article DOI: 10.3389/fimmu.2023.1067352.].
7.
Wan S, Zhao E, Weissinger D, Krantz B, Werba G, Freeman D, et al.
Front Immunol
. 2023 Feb;
14:1067352.
PMID: 36798126
Hepato-pancreatico-biliary (HPB) malignancies are difficult-to-treat and continue to to have a high mortality and significant therapeutic resistance to standard therapies. Immune oncology (IO) therapies have demonstrated efficacy in several solid...
8.
Siolas D, Vucic E, Kurz E, Hajdu C, Bar-Sagi D
Cell Rep
. 2021 Aug;
36(8):109578.
PMID: 34433022
Tumor genotype can influence the immune microenvironment, which plays a critical role in cancer development and therapy resistance. However, the immune effects of gain-of-function Trp53 mutations have not been defined...
9.
Yin L, Criscito M, Stokar E, Siolas D, Haimovic A, Lo Sicco K, et al.
Am J Dermatopathol
. 2021 Jun;
43(10):746-749.
PMID: 34086644
Papillary dermal elastolysis has been described in the setting of experimental combination nivolumab and cabiralizumab immunotherapy. We report a third patient with distinctive, generalized atrophic macules that developed after a...
10.
Siolas D, Morrissey C, Oberstein P
J Pancreatol
. 2020 Nov;
3(3):121-131.
PMID: 33133736
No abstract available.